ASPIVIX Selected Among 4 EVC Finalists - 2017 - Aspivix

ASPIVIX Selected Among 4 EVC Finalists – 2017

October 10, 2017

Share this story:

More from our blog

Aspivix-FDA-510k-FDA-Approved

Aspivix receives U.S. FDA 510(k) Clearance for Carevix™, Their Novel Cervical Stabilizer

Femtech World Blog Cover

Aspivix mentioned in Femtech World about Serie A

Closed Series A+ funding round

ASPIVIX – Manufacturer of non-traumatic medical devices for gynecology – closes $5M Series A+ Funding Round and receives a large EUREKA-EUROSTARS grant co-funded by Innosuisse, the Swiss Innovation Agency.

Female clinician shaking hand of young happy Hispanic patient sitting on couch in medical office after ultrasound examination

10 Simple Steps Gynecologists Can Take to Enhance Patient Experience

Woman stressed about contraceptive myths

5 Common Myths About Contraceptives

aspivix_MG_0208

A modern approach to women’s healthcare

aspivix_MG_0243

Clinical data show significantly lower IUD procedural pain and bleeding rates with Aspivix’s novel suction-based cervical device

News

Aspivix mentioned in Swissquote article about FemTech

News (1)

Reshaping gynecology with women’s experience in mind

News-4

Le grand débat – Santé des femmes, un marché porteur?